{"id":70719,"date":"2026-05-12T09:49:37","date_gmt":"2026-05-12T09:49:37","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70719"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"follistatin-344","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/follistatin-344\/","title":{"rendered":"Follistatina 344"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 a Follistatin 344?<\/h3>\n<p style=\"margin: 0;\"><strong>Follistatina 344<\/strong> (FST-344) is a 344-amino-acid recombinant glycoprotein and the longer of the two principal splice isoforms of human follistatin. It is the canonical endogenous antagonist of myostatin (GDF-8) and activin, used in published studies investigating muscle hypertrophy, sarcopenia, muscular dystrophy preclinical models, and the activin\/myostatin signalling axis. Supplied in 1\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">80449-31-6 (follistatin)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Glicoprote\u00edna recombinante (isoforma de splicing FST-344 de 344 amino\u00e1cidos da follistatin humana)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~37 kDa (forma glicosilada madura; intervalo observado de ~38\u201342 kDa em SDS-PAGE, dependendo do estado de glicosila\u00e7\u00e3o)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estrutura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Dom\u00ednio de liga\u00e7\u00e3o \u00e0 heparina no terminal N seguido por tr\u00eas dom\u00ednios follistatin (FSD1, FSD2, FSD3), cada um contendo um subdom\u00ednio tipo EGF e um subdom\u00ednio tipo Kazal; rico em ciste\u00edna, com m\u00faltiplas liga\u00e7\u00f5es dissulfureto intramoleculares<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prote\u00edna recombinante liofilizada (branca a branco-acinzentado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226595% (verificado por HPLC, COA dispon\u00edvel mediante pedido)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (frigor\u00edfico) para stock de trabalho; \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Reconstitu\u00eddo: 2\u20138 \u00b0C, utilizar dentro de ~30 dias. Proteger da luz. N\u00e3o congelar-descongelar a solu\u00e7\u00e3o reconstitu\u00edda \u2014 as prote\u00ednas recombinantes s\u00e3o particularmente sens\u00edveis \u00e0 desnatura\u00e7\u00e3o por congela\u00e7\u00e3o-descongela\u00e7\u00e3o.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril para per\u00edodos de utiliza\u00e7\u00e3o mais curtos. Prote\u00edna transportadora (BSA, 0,1%) opcional para dilui\u00e7\u00f5es de trabalho, de modo a minimizar perdas por adsor\u00e7\u00e3o.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 a Follistatina 344?<\/h2>\n<p><strong>Follistatina 344<\/strong> (often abbreviated FST-344) is a recombinant 344-amino-acid glycoprotein and the longer of the two principal physiological splice isoforms of human follistatin \u2014 the other being FST-288, a shorter 288-amino-acid membrane-bound form. Endogenous follistatin was first isolated in 1987 from porcine ovarian follicular fluid by Esch et al. (PNAS) and Robertson et al. (Biochem Biophys Res Commun) as a factor that selectively inhibits follicle-stimulating hormone (FSH) secretion, which gave the protein its name. The mechanistic role \u2014 high-affinity binding and neutralisation of activin and myostatin \u2014 was characterised over the subsequent decade. FST-344 is a circulating, secreted isoform with a heparin-binding N-terminal domain followed by three cysteine-rich follistatin domains (FSD1, FSD2, FSD3) that together form the activin- and myostatin-binding surface. The recombinant 344-residue chain has a mature mass of approximately 37\u00a0kDa, with apparent molecular weight on SDS-PAGE varying between 38 and 42\u00a0kDa depending on the glycosylation state of the recombinant expression system. CAS number 80449-31-6. The protein is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. Follistatin is <strong>aprovado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For related anabolic and growth-axis studies, see our <a href=\"https:\/\/medsbase.com\/pt-pt\/igf-1-lr3\/\">IGF-1 LR3<\/a> p\u00e1gina de produto. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Antagonismo da Via da Miostatina e da Activina<\/h2>\n<p>What makes follistatin 344 mechanistically unique among muscle-studies proteins is its <strong>perfil de liga\u00e7\u00e3o multi-alvo<\/strong> across the TGF-\u03b2 superfamily \u2014 each ligand-binding event contributing to the observed hypertrophic and growth-modulatory phenotype in published studies:<\/p>\n<ul>\n<li><strong>Sequestro de miostatina (GDF-8) \u2014 eixo de hipertrofia muscular<\/strong> \u2014 Follistatin binds myostatin (also called GDF-8) with high affinity, sterically blocking its interaction with the activin type II receptor (ActRIIB). Myostatin is the canonical endogenous negative regulator of muscle growth: knockout mice develop dramatic muscle hypertrophy (the &#8220;double-muscling&#8221; phenotype), and naturally myostatin-deficient cattle breeds (Belgian Blue, Piedmontese) show the same effect. By neutralising myostatin, follistatin removes the brake on muscle protein synthesis, producing hypertrophy in study models. This is the most-cited mechanism in the muscle-literature.<\/li>\n<li><strong>Sequestra\u00e7\u00e3o de Activina A e B \u2014 sinaliza\u00e7\u00e3o reprodutiva, ov\u00e1rica e pituit\u00e1ria<\/strong> \u2014 Follistatin&#8217;s original characterised function was binding and neutralising activin, a related TGF-\u03b2 superfamily member that stimulates FSH secretion from the pituitary, drives ovarian follicle development, and acts as a regulator of many cell types. By binding activin A, B, and AB heterodimers, follistatin shifts the activin\/inhibin balance in study models and modulates downstream Smad2\/Smad3 signalling.<\/li>\n<li><strong>Modula\u00e7\u00e3o de GDF-11 e da superfam\u00edlia TGF-\u03b2<\/strong> \u2014 Follistatin also binds GDF-11 (closely related to myostatin) with somewhat lower affinity, alongside other TGF-\u03b2 superfamily members. GDF-11 is increasingly studied in aging studies because its endogenous levels decline with age and its modulation is implicated in age-related cardiac and CNS phenotypes. Follistatin 344 is one of the principal tools for investigating this axis.<\/li>\n<\/ul>\n<p>The three follistatin domains (FSD1, FSD2, FSD3) each contribute to the binding profile: FSD1 contains the principal myostatin-binding surface, FSD2 the principal activin-binding surface, and FSD3 contributes both binding affinity and structural stability. The heparin-binding N-terminal domain distinguishes the splice variants \u2014 FST-288 binds heparan sulfate strongly and is largely membrane-anchored, while FST-344 (this isoform) circulates more freely. This distinction is mechanistically relevant in study models studying systemic vs local follistatin effects. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Follistatin 344 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Muscle hypertrophy and protein synthesis studies<\/strong> \u2014 modelos de hipertrofia em ratos e ratinhos, incluindo estudos de entrega g\u00e9nica AAV-follistatin (Kota et al., Sci Transl Med 2009); \u00e1rea de sec\u00e7\u00e3o transversal espec\u00edfica do tipo de fibra, peso h\u00famido do m\u00fasculo, gera\u00e7\u00e3o de for\u00e7a<\/li>\n<li><strong>Modelos pr\u00e9-cl\u00ednicos de distrofia muscular<\/strong> \u2014 modelo murino mdx de distrofia muscular de Duchenne; capacidade funcional, regenera\u00e7\u00e3o de fibras, preserva\u00e7\u00e3o muscular independente da distrofina<\/li>\n<li><strong>Sarcopenia e perda muscular relacionada com a idade<\/strong> \u2014 aged-mouse muscle phenotypes, anabolic resistance, fibre-type-shift studies<\/li>\n<li><strong>Cancer cachexia studies<\/strong> \u2014 modelos de caquexia em ratos com tumores, preserva\u00e7\u00e3o da composi\u00e7\u00e3o corporal, rela\u00e7\u00e3o massa magra\/massa gorda<\/li>\n<li><strong>Reproductive endocrinology studies<\/strong> \u2014 FSH suppression, ovarian follicle development, granulosa-cell biology, pituitary-gonadal-axis studies<\/li>\n<li><strong>Activin pathway studies<\/strong> \u2014 Smad2\/Smad3 signalling, EMT in cancer models, fibrosis studies, hepatic regeneration<\/li>\n<li><strong>Aging and GDF-11 axis studies<\/strong> \u2014 cardiac and CNS aging phenotypes, parabiosis-related studies, GDF-11\/myostatin balance with aging<\/li>\n<li><strong>Comparative anabolic studies<\/strong> \u2014 compara\u00e7\u00e3o direta com <a href=\"https:\/\/medsbase.com\/pt-pt\/igf-1-lr3\/\">IGF-1 LR3<\/a> (parallel anabolic pathway via IGF-1 receptor) for combined or comparative hypertrophy studies.<\/li>\n<\/ul>\n<p>For broader context on where follistatin 344 fits within the anabolic and growth-axis studies landscape, see <a href=\"https:\/\/medsbase.com\/pt-pt\/igf-1-lr3\/\">IGF-1 LR3<\/a> como o comparador can\u00f3nico do eixo IGF, <a href=\"https:\/\/medsbase.com\/pt-pt\/cjc-1295-with-dac\/\">CJC-1295 com DAC<\/a> for GHRH-axis growth studies, and <a href=\"https:\/\/medsbase.com\/pt-pt\/sermorelin\/\">Sermorelin<\/a> for shorter-acting GHRH use. Browse the full <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para encontrar compostos relacionados. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks Follistatin 344 in 1\u00a0mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>1 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 muscle hypertrophy and activin\/myostatin axis studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Follistatin 344 is a 37\u00a0kDa recombinant glycoprotein supplied at \u226595% HPLC purity. The 1\u00a0mg vial format is the standard strength for in vivo and in vitro work \u2014 one vial reconstituted with 1.0\u00a0mL bacteriostatic water yields a 1\u00a0mg\/mL working concentration sufficient for many weeks of cell-culture protocols or several rodent-protocol injections. <\/p>\n<h2>Compara\u00e7\u00e3o \u2014 Follistatin 344 vs IGF-1 LR3<\/h2>\n<p>A Follistatin 344 e o <a href=\"https:\/\/medsbase.com\/pt-pt\/igf-1-lr3\/\">IGF-1 LR3<\/a> are the two most-cited recombinant anabolic proteins in current hypertrophy studies. They act on entirely different pathways \u2014 follistatin by removing the myostatin brake on muscle growth, IGF-1 LR3 by directly stimulating the IGF-1 receptor and downstream Akt\/mTOR protein synthesis \u2014 which makes them mechanistically complementary in protocols. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Follistatina 344<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">IGF-1 LR3<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Comprimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">344 amino\u00e1cidos (glicoprote\u00edna recombinante)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">83 amino\u00e1cidos (IGF-1 modificado)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~37 kDa<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~9 kDa<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Mecanismo prim\u00e1rio<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sequestro de miostatina\/activina<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Agonismo do recetor IGF-1 \u2192 Akt\/mTOR<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Modo de efeito<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Desinibi\u00e7\u00e3o (remove o trav\u00e3o de crescimento)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Estimula\u00e7\u00e3o anab\u00f3lica direta<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u2013100 mcg, 1\u20133x por semana<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">20\u201360 mcg, diariamente<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Hipertrofia muscular global, modelos de distrofia<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Local hypertrophy, regenerative anabolic studies<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Empilhamento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Commonly co-administered with IGF-1 LR3 in hypertrophy studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Frequentemente coadministrado com follistatina 344<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Because the two proteins act on fundamentally different anabolic axes \u2014 follistatin removes the myostatin brake while IGF-1 LR3 directly stimulates protein synthesis \u2014 combined administration is commonly used in study models exploring maximal hypertrophic response. For studies interested in the myostatin pathway specifically, follistatin 344 is the canonical first choice; for IGF\/Akt\/mTOR anabolic studies, IGF-1 LR3 is the canonical tool. <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene os frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para stock de trabalho a curto prazo. Para armazenamento a longo prazo sem abertura, congele a \u221220 \u00b0C. A follistatina 344 liofilizada \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o por at\u00e9 12 meses e a \u221220 \u00b0C por at\u00e9 24 meses \u2014 um per\u00edodo ligeiramente mais curto do que o dos pequenos p\u00e9ptidos sint\u00e9ticos, uma vez que a glicoprote\u00edna recombinante maior \u00e9 mais suscet\u00edvel a desamida\u00e7\u00e3o e oxida\u00e7\u00e3o ao longo do tempo. Evite ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o no p\u00f3 liofilizado. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> injecte \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco do p\u00e9ptido (n\u00e3o diretamente sobre o p\u00f3 liofilizado). Para um frasco de 1 mg, 1,0 mL de \u00e1gua bacteriost\u00e1tica produz uma concentra\u00e7\u00e3o de trabalho de 1 mg\/mL. Agite suavemente \u2014 n\u00e3o <strong>n\u00e3o<\/strong> agite vigorosamente \u2014 e aguarde 5\u201310 minutos para dissolu\u00e7\u00e3o completa. As prote\u00ednas recombinantes dissolvem-se mais lentamente do que os pequenos p\u00e9ptidos; n\u00e3o apresse o passo de dissolu\u00e7\u00e3o. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda deve ser l\u00edmpida e incolor, sem part\u00edculas vis\u00edveis. Para dilui\u00e7\u00f5es de trabalho abaixo de 100 mcg\/mL, a adi\u00e7\u00e3o de prote\u00edna transportadora (BSA a 0,1% de concentra\u00e7\u00e3o final) minimiza as perdas por adsor\u00e7\u00e3o em pl\u00e1stico e vidro. <strong>Ap\u00f3s reconstitui\u00e7\u00e3o:<\/strong> armazene refrigerado a 2\u20138 \u00b0C e utilize no prazo de 30 dias para estabilidade \u00f3tima. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 as glicoprote\u00ednas recombinantes s\u00e3o particularmente sens\u00edveis \u00e0 desnatura\u00e7\u00e3o por congela\u00e7\u00e3o-descongela\u00e7\u00e3o, o que produz agrega\u00e7\u00e3o e perda de atividade. Descarte qualquer frasco que apresente turva\u00e7\u00e3o, precipitado ou descolora\u00e7\u00e3o. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is Follistatin 344 used for in studies?<\/h3>\n<p>Follistatin 344 is used in studies investigating muscle hypertrophy, muscular dystrophy preclinical models, sarcopenia, cancer cachexia, the activin\/myostatin\/GDF-11 signalling axis, reproductive endocrinology (FSH suppression, ovarian follicle development), and aging-related phenotypes. It is the canonical tool for myostatin pathway antagonism. The pharmaceutical-grade follistatin 344 sold here is <strong>n\u00e3o<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>Qual \u00e9 a diferen\u00e7a entre a Follistatin 344 e a Follistatin 315?<\/h3>\n<p>A FST-344 \u00e9 a isoforma do produto gen\u00e9tico de 344 amino\u00e1cidos que inclui o p\u00e9ptido sinal; a FST-315 \u00e9 a mesma prote\u00edna ap\u00f3s a clivagem do p\u00e9ptido sinal durante a secre\u00e7\u00e3o (portanto, a FST-315 \u00e9 a forma circulante madura da FST-344). Ambos os sistemas de nomenclatura aparecem na literatura e referem-se \u00e0 mesma isoforma biol\u00f3gica. Ambos diferem substancialmente da FST-288, que \u00e9 uma isoforma mais curta, resultante de splicing alternativo, com maior liga\u00e7\u00e3o ao sulfato de heparano e localiza\u00e7\u00e3o maioritariamente ligada \u00e0 membrana. <\/p>\n<h3>Como \u00e9 que a Follistatin 344 difere do IGF-1 LR3?<\/h3>\n<p>Both are recombinant anabolic proteins used in muscle hypertrophy studies, but they target different pathways. Follistatin 344 is a 344-amino-acid glycoprotein that binds and sequesters myostatin and activin \u2014 it works by removing the endogenous brake on muscle growth. IGF-1 LR3 is an 83-amino-acid modified IGF-1 analog that directly agonises the IGF-1 receptor and activates Akt\/mTOR protein synthesis. The two are mechanistically complementary and frequently co-administered in studies. <\/p>\n<h3>What is the typical Follistatin 344 dose?<\/h3>\n<p>Published preclinical protocols typically use 10\u2013100\u00a0mcg per administration in rodent models, given 1\u20133 times weekly for 4\u201312 week cycles. Gene-delivery studies using AAV-follistatin produces tissue-localised concentrations that are difficult to compare directly to systemic-protein dosing. A 1\u00a0mg vial reconstituted with 1.0\u00a0mL bacteriostatic water yields 1\u00a0mg\/mL \u2014 0.01\u00a0mL equals 10\u00a0mcg, 0.1\u00a0mL equals 100\u00a0mcg. <\/p>\n<h3>A Follistatin 344 \u00e9 aprovada pela FDA?<\/h3>\n<p>No. Follistatin 344 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. AAV-follistatin gene therapy has been investigated in clinical trials for muscular dystrophy (e.g., Becker muscular dystrophy, inclusion body myositis) but is not FDA-approved. <\/p>\n<h3>Como deve ser armazenada a Follistatin 344?<\/h3>\n<p>Frascos liofilizados: refrigerados a 2\u20138\u00a0\u00b0C para stock de trabalho a curto prazo, ou \u221220\u00a0\u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerada a 2\u20138\u00a0\u00b0C, utilizar no prazo de 30 dias. N\u00e3o congelar a solu\u00e7\u00e3o reconstitu\u00edda \u2014 as glicoprote\u00ednas recombinantes s\u00e3o particularmente sens\u00edveis \u00e0 desnatura\u00e7\u00e3o por congela\u00e7\u00e3o-descongela\u00e7\u00e3o. Proteger da luz direta em todos os momentos. A prote\u00edna transportadora (BSA a 0,1%) \u00e9 recomendada para dilui\u00e7\u00f5es de trabalho abaixo de 100\u00a0mcg\/mL. <\/p>\n<h3>Como reconstituir a Follistatin 344?<\/h3>\n<p>Siga o procedimento de reconstitui\u00e7\u00e3o acima. Adicione \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o liofilizado), agite suavemente e aguarde 5 a 10 minutos para dissolu\u00e7\u00e3o completa. N\u00e3o <strong>n\u00e3o<\/strong> Agite o frasco \u2014 uma agita\u00e7\u00e3o vigorosa pode desnaturar prote\u00ednas recombinantes e causar agrega\u00e7\u00e3o. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda \u00e9 l\u00edmpida e incolor. Para um frasco de 1 mg + 1,0 mL de diluente, a concentra\u00e7\u00e3o de trabalho \u00e9 de 1 mg\/mL. <\/p>\n<h3>Por que \u00e9 que a especifica\u00e7\u00e3o de pureza \u00e9 de 95% em vez de 99%?<\/h3>\n<p>Recombinant glycoproteins like follistatin 344 cannot achieve the \u226599% HPLC purity standard typical of small synthetic peptides because of the inherent heterogeneity of glycosylation in any recombinant expression system \u2014 different glycoforms appear as related peaks on HPLC that are not impurities but isoforms of the target protein. \u226595% HPLC purity is the standard pharmaceutical-grade specification for follistatin 344 and similar recombinant glycoproteins. SDS-PAGE typically shows a single band with the expected 38\u201342\u00a0kDa apparent mass range. <\/p>\n<h3>Que dosagens est\u00e3o dispon\u00edveis na MedsBase?<\/h3>\n<p>MedsBase carries Follistatin 344 in 1\u00a0mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at \u226595% HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Can Follistatin 344 and IGF-1 LR3 be stacked in studies?<\/h3>\n<p>Yes. Follistatin 344 and IGF-1 LR3 act on fundamentally different anabolic axes (myostatin antagonism vs IGF-1 receptor agonism) and are frequently co-administered in study models exploring maximal hypertrophic response. The two are mechanistically complementary rather than redundant, and combined-protocol literature describes additive or synergistic effects on muscle fibre cross-sectional area. <\/p>\n<h3>Does Follistatin 344 cause side reported effects?<\/h3>\n<p>Published preclinical studies has documented tolerability at typical doses, with the main on-target effect being muscle hypertrophy. Off-target findings include modulation of FSH and ovarian function (because activin signalling is suppressed) and potential effects on hepatic regeneration and pituitary regulation due to follistatin&#8217;s role in broader TGF-\u03b2 superfamily signalling. Systemic follistatin-protein dosing has different exposure characteristics than tissue-localised AAV-gene-delivery approaches. <\/p>\n<h3>Qual \u00e9 a meia-vida da Follistatin 344?<\/h3>\n<p>In preclinical studies, recombinant follistatin 344 has a plasma half-life of approximately 1\u20133 hours following intravenous administration, reflecting its size (37\u00a0kDa, above the renal filtration cutoff) and binding to circulating ligands. Tissue half-life is considerably longer because follistatin remains bound to its captured myostatin and activin targets, sequestering them away from receptors. Gene-delivery approaches produce a far longer effective duration of action because tissue expression continues over weeks to months. <\/p>\n<h3>How long does Follistatin 344 take to show effects in preclinical studies?<\/h3>\n<p>Os efeitos de hipertrofia muscular em protocolos de inje\u00e7\u00e3o de prote\u00edna em ratos e camundongos tornam-se estatisticamente significativos ap\u00f3s 2\u20134 semanas de administra\u00e7\u00e3o semanal e continuam a acumular-se at\u00e9 \u00e0s 8\u201312 semanas. Os efeitos no eixo Activina\/FSH em par\u00e2metros reprodutivos podem ser detetados poucos dias ap\u00f3s a administra\u00e7\u00e3o. Protocolos de entrega g\u00e9nica (AAV-folistatina) mostram hipertrofia muscular mensur\u00e1vel \u00e0s 4\u20136 semanas p\u00f3s-inje\u00e7\u00e3o e continuam a desenvolver-se ao longo de meses. <\/p>\n<h3>Posso encomendar Follistatin 344 para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia Follistatin 344 para todo o mundo a partir da nossa rede dedicada de envio de p\u00e9ptidos. As encomendas exclusivas de p\u00e9ptidos qualificam-se para o nosso servi\u00e7o de envio aut\u00f3nomo de p\u00e9ptidos. Todas as encomendas s\u00e3o enviadas em embalagens com controlo de temperatura, com rastreio completo e est\u00e3o cobertas pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\">Pol\u00edtica de Garantia de Reenvio<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Anabolic, Growth-Axis, and Muscle Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-pt\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 Long-arginine recombinant IGF-1 analog \u2014 direct IGF-1R agonist for Akt\/mTOR studies<\/li>\n<li><a href=\"\/pt-pt\/cjc-1295-with-dac\/\"><strong>CJC-1295 com DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 growth hormone axis support<\/li>\n<li><a href=\"\/pt-pt\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 Shorter-acting GHRH(1-29) analog \u2014 natural GH-pulse support<\/li>\n<li><a href=\"\/pt-pt\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Agonista selectivo de grelina \u2014 pulso de GH limpo sem cortisol\/prolactina<\/li>\n<li><a href=\"\/pt-pt\/tb-500\/\"><strong>TB-500 (Thymosin Beta-4)<\/strong><\/a> \u2014 Systemic healing fragment \u2014 muscle and cardiac recovery<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore anabolic and growth-axis peptides<\/strong><\/p>\n<p style=\"margin: 0;\">Explore a gama completa <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, com compostos relacionados incluindo <a href=\"https:\/\/medsbase.com\/pt-pt\/igf-1-lr3\/\">IGF-1 LR3<\/a> for direct IGF-receptor anabolic studies, <a href=\"https:\/\/medsbase.com\/pt-pt\/cjc-1295-with-dac\/\">CJC-1295 com DAC<\/a> for long-acting GHRH use, and <a href=\"https:\/\/medsbase.com\/pt-pt\/tb-500\/\">TB-500<\/a> for systemic muscle and tissue recovery.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Glicoprote\u00edna recombinante de 344 amino\u00e1cidos<br \/>\n\u2705 Antagonista da via da miostatina e da activina<br \/>\n\u2705 Muscle hypertrophy compound<br \/>\n\u2705 Modelos pr\u00e9-cl\u00ednicos de distrofia muscular<br \/>\n\u2705 Pureza \u226595% por HPLC, COA dispon\u00edvel mediante pedido<\/p>\n<p><strong>Follistatina 344<\/strong> \u00e9 uma prote\u00edna recombinante.<\/p>","protected":false},"featured_media":70949,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6276,5441],"class_list":["post-70719","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-follistatin","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/70719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=70719"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/70949"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=70719"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=70719"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=70719"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=70719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}